A randomized controlled trial on the effects and acceptability of individual mindfulness techniques – meditation and yoga – on anxiety and depression in people with Parkinson’s disease: a study protocol.

Publication date: Jul 17, 2023

Between 40 and 50% of patients with Parkinson’s disease (PD) experience anxiety and depression, associated with impaired physical function, high care dependency and mortality. Recently, the United States National Institutes of Health has urged the implementation of mindfulness practices in chronic illness care. Most research to date has examined the effects on chronically ill patients of complex interventions using a combination of mindfulness techniques. In PD patients, however, such complex modalities appear to hinder the technique mastery. Hence, the aim of this trial is to investigate the effects and underlying mechanism of individual mindfulness techniques among PD patients, as well as exploring participants’ experience in using individual mindfulness techniques as a lifestyle intervention for stress and symptom management. We will conduct an assessor-blind three-arm randomized waitlist-controlled trial with a descriptive qualitative evaluation. Up to 168 PD patients will be recruited from community settings and out-patient clinics, and randomized to meditation, yoga, or usual care group. Meditation and yoga sessions of 90-minute are held weekly for 8 weeks. Primary outcomes include anxiety and depression. Secondary outcomes include PD-related motor and non-motor symptoms and quality-of-life; and level of mindfulness and biomarkers of stress and inflammatory responses will be measured as mediating variables. All outcome evaluations will be assessed at baseline, 8 weeks, and 24 weeks. Following the intention-to-treat principle, generalized estimating equation models and path analysis will be used to identify the treatment effects and the mediating mechanisms. A subsample of 30 participants from each intervention group will be invited for qualitative interviews. The study would also generate important insights to enhance the patients’ adaptation to debilitating disease. More specifically, symptom management and stress adaptation are highly prioritized healthcare agenda in managing PD. The research evidence will further inform the development of community-based, nurse-led compassionate care models for neurodegenerative conditions, which is complementary to existing health services. WHO Primary Registry – Chinese Clinical Trials Registry number: ChiCTR2100045939; registered on 2021/04/29 ( https://www. chictr. org. cn/showproj. html?proj=125878 ).

Open Access PDF

Concepts Keywords
Chictr2100045939 Anxiety
Debilitating Chronic illness care
Healthcare Depression
Parkinson Meditation
Parkinson’s disease
Psychological distress
Quality of life


Type Source Name
disease MESH chronic illness
disease MESH lifestyle
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH neurodegenerative disease
disease MESH cognitive impairment
disease MESH insomnia
disease MESH psychological distress
drug DRUGBANK Trestolone
drug DRUGBANK Hydrocortisone
disease MESH chronic pain
disease MESH cardiovascular diseases
disease MESH postures
drug DRUGBANK Ranitidine
drug DRUGBANK Ademetionine
disease MESH contraindication
disease MESH comorbidity
drug DRUGBANK Dimercaprol
disease MESH Movement Disorder
disease MESH apathy
drug DRUGBANK Dopamine
disease MESH gait
disease MESH complications
disease MESH dyskinesia
disease MESH marital status
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Oxidative stress
disease MESH uncertainty
disease MESH Parkinsonism
disease MESH Inflammation
disease MESH Parkinson Disease
pathway KEGG Parkinson disease
drug DRUGBANK Rotigotine
disease MESH hypercortisolism
disease MESH psychological stress

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *